melasma melasma, 675-nm Red Laser
Conditions
Interventions
Participant receive 3 session of 675-nm Red Laser. Participants then receive follow up treatment at 1-3 and 6 months after complete treatment
Experimental Device
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Participants aged 18 years and older, both male and female. 2. Asian participants with Fitzpatrick Skin Type III-V. 3. Participants diagnosed with melasma by the researching physician. 4. Participants with melasma on both sides of the face. 5. Participants who consent to join the project voluntarily and agree to receive laser treatment at the positions specified in the research protocol.
Exclusion criteria
Exclusion criteria: 1. Participants who are pregnant or breastfeeding. 2. Participants with inflammatory skin rashes, wounds, or infections on the face. 3. Participants with light-sensitive rashes such as various photodermatitis, lupus erythematosus, and those with a history of skin cancer on the face. 4. Participants who have used hormones or contraceptives within the last 3 months. 5. Participants who have been treated for melasma with topical or oral medications within the last 3 months. 6. Participants who have been treated for melasma with facial laser treatments within the last 3 months. 7. Participants who have been treated with platelet-rich plasma injections within the last 12 months. 8. Participants who have received facial injections to stimulate collagen or reduce hyperpigmentation, such as polycaprolactone, hyaluronic acid, polydioxanone, poly-L-lactic acid, or calcium hydroxyapatite within the last 12 months. 9. Participants with severe chronic illnesses such as advanced-stage cancer or end-stage renal failure. 10. Participants diagnosed with a mental disorder by a psychiatrist. 11. Participants who do not consent to having photographs taken for treatment assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average melanin baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatment Antera 3D,Average erythema baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatmen Antera 3D,Melanin level baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatmen Mexameter,Erythema level baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatmen Mexameter | — |
Secondary
| Measure | Time frame |
|---|---|
| physician assessment score baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatmen clinical photos,patient assessment baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatment global aesthetic improvement score,adverse event baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatmen note,pain score baseline, 1month after 1st treatment, 1 month after 2nd treatment visual analog score,mMasi score baseline, 1month after 1st treatment, 1 month after 2nd treatment , 1-,3-,and 6 months after complete treatment mMasi score | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed